Bio-Techne Corp at Morgan Stanley Global Healthcare Conference Transcript
Hi, everybody. My name is Valerie Dixon. I'm a Managing Director at Morgan Stanley, and I lead the firm's coverage efforts in life sciences tools and diagnostics. We're happy to have today, Bio-Techne in our fireside chat and the CEO, Chuck Kummeth, to tell us a little bit about the story and why we're excited about Bio-Techne today.
We just had actually an interesting and very well-attended Analyst Day for you all last Friday in New York. So we're going to try to uncover some new gems and why you should get into the story now. But for those who did not make that event and want to learn a little bit more about Techne, why don't you just kick us off, Chuck, with a few minutes on Bio-Techne?
Sure. Well, we describe ourselves as truly a life science tools and diagnostics company. We're a portfolio of a diversified platform, roughly a dozen. The company is actually 47 years old, has a pretty good stock ticker symbol, TECH, and started out as a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
